Drug Type Small molecule drug |
Synonyms Gentiopicroside, QINGLONG KUSU |
Target |
Action inhibitors, agonists |
Mechanism SRD5A2 inhibitors(Steroid 5 alpha reductase 2 inhibitors), TGR5 agonists(G-protein coupled bile acid receptor 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H20O9 |
InChIKeyDUAGQYUORDTXOR-GPQRQXLASA-N |
CAS Registry20831-76-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B | Phase 3 | - | - | |
Parkinson Disease | Preclinical | China | 23 May 2025 |